Disease · HP_0001337

Tremor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Tremor. Diseases, record HP_0001337. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001337

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Tremor
Open Targets ID: HP_0001337
Other names: Tremors
Highest stage of its drugs: Phase 3, for 2 of its 11 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
GABAPENTIN	CHEMBL940	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM OXYBATE	CHEMBL1200682	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
TACROLIMUS	CHEMBL3989887	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SUVECALTAMIDE	CHEMBL1684950	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ZONISAMIDE	CHEMBL750	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OCTANOIC ACID	CHEMBL324846	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
OCTANOL	CHEMBL26215	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVODOPA	CHEMBL1009	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets44

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CACNA1G	Voltage-gated T-type calcium channel	2	Voltage-gated T-type calcium channel modulator; Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/8913	Drugs and targets
CACNA1H	Voltage-gated T-type calcium channel	2	Voltage-gated T-type calcium channel modulator; Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/8912	Drugs and targets
CACNA1I	Voltage-gated T-type calcium channel	2	Voltage-gated T-type calcium channel modulator; Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/8911	Drugs and targets
DRD3	D(3) dopamine receptor	2	D2-like dopamine receptor agonist; Dopamine D3 receptor agonist	Unknown	https://conductscience.org/library/genes/1814	Drugs and targets
CACNA1A	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/773	Drugs and targets
CACNA1B	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/774	Drugs and targets
CACNA1C	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1E	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/777	Drugs and targets
CACNA1F	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Phase 3	https://conductscience.org/library/genes/778	Drugs and targets

1 to 10 of 44

See all 44 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03292458	Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor	Phase 2/3	117	2025-04-04	Spasmodic Dysphonia, Voice Tremor	SODIUM OXYBATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03582137	A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease	Phase 2	74	2024-07-23	Parkinson Disease	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT01961297	Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response	Phase 2	53	2017-11-22	Spasmodic Dysphonia, Voice Tremor	SODIUM OXYBATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00848172	Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor	Phase 1/2	29	2012-12-27	Essential Tremor	OCTANOIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02818777	A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease	Phase 2	13	2019-02-19	Parkinson's Disease	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT02231294	The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease		1,464		Parkinson Disease	PRAMIPEXOLE	Its record names the disease	ClinicalTrials.gov
NCT00016679	1-Octanol to Treat Essential Tremor	Phase 1	42		Essential Tremor	OCTANOL	Its record names the disease	ClinicalTrials.gov
NCT00533455	Gabapentin for the Treatment of Neuroleptic-Induced Tremor	Phase 3	40		Neuroleptic-Induced Tremor	GABAPENTIN	Its record names the disease	ClinicalTrials.gov
NCT00223743	A Safety/Efficacy Trial of Zonisamide for Essential Tremor	Phase 2	25		Essential Tremor	ZONISAMIDE	Its record names the disease	ClinicalTrials.gov
NCT03769298	CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients	Phase 2/3	20		Kidney Pancreas Transplantation	TACROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CBD Cannabis Extract Oral Solution vs Placebo: Difference in Proportion of Participants That Discontinue the Study Due to Study Drug Intolerance	1 of 31	0 of 30	61	NCT03582137	Trial comparisons
CBD Cannabis Extract Oral Solution vs Placebo: Change in Liver Function Monitoring --Liver Function Test	0 of 31	0 of 30	61	NCT03582137	Trial comparisons
CBD Cannabis Extract Oral Solution vs Placebo: Change in Laboratory Values--chemistry	0 of 31	0 of 30	61	NCT03582137	Trial comparisons
CBD Cannabis Extract Oral Solution vs Placebo: Change in Neurological Exam	0 of 31	0 of 30	61	NCT03582137	Trial comparisons
CBD Cannabis Extract Oral Solution vs Placebo: Change in Physical Exam	0 of 31	0 of 30	61	NCT03582137	Trial comparisons
CBD Cannabis Extract Oral Solution vs Placebo: Change in Electrocardiograms	0 of 31	0 of 30	61	NCT03582137	Trial comparisons
CBD Cannabis Extract Oral Solution vs Placebo: The Number of Participants Wtih Treatment-related Adverse Events	26 of 31	25 of 30	61	NCT03582137	Trial comparisons
CBD Cannabis Extract Oral Solution vs Placebo: deaths from any cause	0 of 31	0 of 30	61	NCT03582137	Trial comparisons
CBD Cannabis Extract Oral Solution vs Placebo: Change in Laboratory Values--hematology	0 of 31	0 of 30	61	NCT03582137	Trial comparisons
CBD Cannabis Extract Oral Solution vs Placebo: serious adverse events	1 of 31	0 of 30	61	NCT03582137	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27808415	RESULT	1	PubMed
40265962	DERIVED	1	PubMed
38466972	DERIVED	1	PubMed
37448353	DERIVED	1	PubMed
30382161	DERIVED	1	PubMed
25929664	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001337

GET https://conductscience.org/api/diseases/v1/HP_0001337/targets?page=2

API reference For AI assistants